Preventing and Treating Anthracycline Cardiotoxicity: New Insights

被引：124
作者：
Sawicki, Konrad Teodor [1 ]
Sala, Valentina [2 ]
Prever, Lorenzo [2 ]
Hirsch, Emilio [2 ]
Ardehali, Hossein [1 ]
Ghigo, Alessandra [2 ]
机构：
[1] Northwestern Univ, Feinberg Sch Med, Feinberg Cardiovasc & Renal Res Inst, Div Cardiol, Chicago, IL 60611 USA
[2] Univ Torino, Dept Mol Biotechnol & Hlth Sci, I-10126 Turin, Italy
来源：
ANNUAL REVIEW OF PHARMACOLOGY AND TOXICOLOGY, VOL 61, 2021 | 2021年 / 61卷
关键词：
anthracyclines; doxorubicin; cardiotoxicity; left ventricular dysfunction; heart failure; oxidative stress; DOXORUBICIN-INDUCED CARDIOTOXICITY; SECONDARY ALCOHOL METABOLITE; ACUTE LYMPHOBLASTIC-LEUKEMIA; GENOME-WIDE ASSOCIATION; BREAST-CANCER PATIENTS; OXIDATIVE STRESS; HEART-FAILURE; RISK-FACTORS; CARDIOMYOCYTE APOPTOSIS; GENETIC POLYMORPHISMS;
D O I：
10.1146/annurev-pharmtox-030620-104842
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
Anthracyclines are the cornerstone of many chemotherapy regimens for a variety of cancers. Unfortunately, their use is limited by a cumulative dose-dependent cardiotoxicity. Despite more than five decades of research, the biological mechanisms underlying anthracycline cardiotoxicity are not completely understood. In this review, we discuss the incidence, risk factors, types, and pathophysiology of anthracycline cardiotoxicity, as well as methods to prevent and treat this condition. We also summarize and discuss advances made in the last decade in the comprehension of the molecular mechanisms underlying the pathology.
引用
收藏
页码：309 / 332
页数：24
相关论文
共 168 条
[31]  
DIMARCO A, 1981, CANCER TREAT REP, V65, P3
[32]  
DOROSHOW JH, 1986, J BIOL CHEM, V261, P3068
[33]   Protease proteomics: Revealing protease in vivo functions using systems biology approaches [J].
Doucet, Alain ;
Overall, Christopher M. .
MOLECULAR ASPECTS OF MEDICINE, 2008, 29 (05) :339-358
[34]   Possible role of brain-derived neurotrophic factor in the pathogenesis of coronary artery disease [J].
Ejiri, J ;
Inoue, N ;
Kobayashi, S ;
Shiraki, R ;
Otsui, K ;
Honjo, T ;
Takahashi, M ;
Ohashi, Y ;
Ichikawa, S ;
Terashima, M ;
Mori, T ;
Awano, K ;
Shinke, T ;
Shite, J ;
Hirata, K ;
Yokozaki, H ;
Kawashima, S ;
Yokoyama, M .
CIRCULATION, 2005, 112 (14) :2114-2120
[35]   A mathematical model for comparison of bolus injection, continuous infusion, and liposomal delivery of doxorubicin to tumor cells [J].
El-Kareh, AW ;
Secomb, TW .
NEOPLASIA, 2000, 2 (04) :325-338
[36]   Chelation therapy in cardiovascular disease: Ethylenediaminetetraacetic acid, deferoxamine, and dexrazoxane [J].
Elihu, N ;
Anandasbapathy, S ;
Frishman, WH .
JOURNAL OF CLINICAL PHARMACOLOGY, 1998, 38 (02) :101-105
[37]   Ferroptosis as a target for protection against cardiomyopathy [J].
Fang, Xuexian ;
Wang, Hao ;
Han, Dan ;
Xie, Enjun ;
Yang, Xiang ;
Wei, Jiayu ;
Gu, Shanshan ;
Gao, Feng ;
Zhu, Nali ;
Yin, Xiangju ;
Cheng, Qi ;
Zhang, Pan ;
Dai, Wei ;
Chen, Jinghai ;
Yang, Fuquan ;
Yang, Huang-Tian ;
Linkermann, Andreas ;
Gu, Wei ;
Min, Junxia ;
Wang, Fudi .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2019, 116 (07) :2672-2680
[38]  
FERRANS VJ, 1978, CANCER TREAT REP, V62, P955
[39]   Pharmacokinetics of pegylated liposomal doxorubicin - Review of animal and human studies [J].
Gabizon, A ;
Shmeeda, H ;
Barenholz, Y .
CLINICAL PHARMACOKINETICS, 2003, 42 (05) :419-436
[40]   Toxicity prevention with amifostine in pediatric osteosarcoma patients treated with cisplatin and doxorubicin [J].
Gallegos-Castorena, Sergio ;
Martinez-Avalos, Armando ;
Mohar-Betancourt, Alejandro ;
Guerrero-Avendano, Guadalupe ;
Zapata-Tarres, Martha ;
Medina-Sanson, Aurora .
PEDIATRIC HEMATOLOGY AND ONCOLOGY, 2007, 24 (5-8) :403-408
12345678910